drugset / Trial / NCT00720148

A Phase I Trial of Bortezomib and Sunitinib

NCT00720148

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the effect of the combination of sunitinib and bortezomib. We will see what effects it has on your cancer and find the highest dose of each agent that can be given without causing severe side effects.

Timeline

Start
2008-02
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule Intravenous
Subject Sunitinib Small molecule Oral

Indications